With the rapid increase in obesity there has been a pronounced increase in obesity-related metabolic disorders including type 2 diabetes, cardiovascular disease, dyslipidaemia and hypertension. Bariatric surgery is a highly effective treatment for achieving long-term weight loss and is increasingly recognised to have benefits in diabetes treatment and cause improvement in other metabolic factors. Recent small randomised trials reported better glycaemic control after surgical intervention compared to pharmacological therapy. Physiological studies suggest a surgery-specific, weight-independent effect on glucose homeostasis. Long-term efficacy is to be proven. Consensus on definition of diabetes and diabetes remission must be achieved. Larger multicentre, randomised trials need to be done to clarify the place of metabolic surgery in diabetes treatment algorithms.
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With the rapid increase in obesity there has been a pronounced increase in obesity-related metabolic disorders including type 2 diabetes, cardiovascular disease, dyslipidaemia and hypertension. 2 Type 2 diabetes is a multi-factorial disorder and obesity is considered the most important risk factor. The prevalence of obesity among adults with diagnosed diabetes is over 50 %, and the prevalence of overweight is over 80 %. 3 It has been estimated that the risk of developing type 2 diabetes is increased 93-fold in women and 42-fold in men who are severely obese (BMI ≥ 35 kg/m 2 ) rather than of healthy weight. 4, 5 Given this information, weight loss is one of the most important treatment strategies to obtain good glycaemic control (glycated haemoglobin [HbA 1c ] <7 %). Intentional weight loss of at least 5 % to 10 % of body weight has repeatedly been shown to improve glycaemic control and cardiovascular risk profiles in obese subjects with type 2 diabetes. [6] [7] [8] Type 2 diabetes is usually a progressive disease characterised by both a loss of insulin secretory capacity of the pancreatic ß-cells over time and insulin resistance, resulting in progressive hyperglycaemia and subsequent micro-and macrovascular complications. This natural course requires a continuous monitoring and intensification of the therapy with adding new pharmacological agents. Unfortunately, a number of hypoglycaemic agents, including insulin, sulphonylurea and thiazolidinediones exacerbate weight gain.
In the long term, all conservative medical and lifestyle treatments of obesity often fail to achieve sufficient blood glucose control in morbidly obese patients. The mean maintenance weight loss after conservative interventions for obesity is <25 % after 2 years. 9 Bariatric surgery is a highly effective treatment for achieving long-term weight loss in adults with obesity. 10 Moreover, bariatric surgery is increasingly recognised to have benefits in diabetes treatment and can also be associated with improvements or normalisation in blood pressure, lipid profile, quality of life and obstructive sleep apnoea syndrome.
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Types of Bariatric Surgery and Indications
The disappointing results of medical treatments, along with the growing incidence of obesity and its related life-threatening complications, has led to the widespread use of bariatric surgery. which means a decline of 24.5 % compared with 2008. Nowadays, the biliopancreatic diversion/duodenal switch is less used (2.2% in 2011). 12 The outcome on weight loss and other metabolic parameters and the short-and long-term risks depends on the type of surgical procedure.
A meta-analysis of Buchwald et al. in 2004 including 22,094 patients reported a mean percentage of excess weight loss of 61.2 % for all types of bariatric surgical procedures. It was less for AGB (47.5 %) compared with gastric bypass (61.6 %), gastroplasty (68.2 %) and biliopancreatic diversion or duodenal switch (70.1 %). 13 The 2009 Cochrane review analysed the results of 26 studies including patients with and without diabetes. They concluded that bariatric surgery resulted in greater weight loss than conventional treatment in individuals with moderate obesity (BMI >30 kg/m²) as well as in patients with severe obesity. Reductions in co-morbidities, such as diabetes and hypertension, as well as improvements in health-related quality of life were noted. 11 The large prospective Swedish Obesity Study (SOS) reported that, after 10 years, weight loss of 25 % of body weight had been successfully maintained in surgical objects, compared with 1.5 % in non-surgical patients. 14 According to the 1991 National Institutes of Health Consensus Conference Guidelines, patients are considered as surgical candidates only if their BMI ≥ 40 kg/m² or if their BMI is ≥ 35 and they suffer from obesity-related co-morbidities, such as hypertension, cardiovascular disease, sleep apnoea and type 2 diabetes. 15 Nowadays, there is a growing appreciation for the role of bariatric surgery as a tool in diabetic management. There are indications that patients with poorly controlled type 2 diabetes and a BMI lower than 35 kg/m² may also benefit from bariatric surgery. However, further evidence is needed to support these recommendations. However, it is important to note that all of these studies used less strict criteria for diabetes remission than those proposed by a consensus statement in 2009. These data indicate that an improved glycaemic control rather than remission could be expected after this type of surgery.
Effects of Bariatric Surgery on Diabetes
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Until recently, no randomised trials were performed to evaluate whether glycaemic control improved more in patients undergoing bariatric surgery compared with intensive medical therapy. The primary endpoint (HbA 1c ≤ 6.0 % after one year) was achieved in 42 % of the gastric bypass group and 37 % of the sleeve-gastrectomy group versus 12 % of the medical-therapy group. 20 Very recently, the results of 2-year follow-up of 60 patients of the initial study were published. At 24 months, the proportion of patients with HbA 1c ≤ 6.0 % decreased in the sleeve gastrectomy group from 26 % to 11 % but persisted in the RYBG group (from 44 % to 33 %). Despite similar weight loss, the absolute reduction in percent truncal fat was greater in gastric bypass versus sleeve gastrectomy group. In gastric bypass patients, normal glucose tolerance and pancreatic ß-cell function were restored in contrast with sleeve gastrectomy where insulin sensitivity was only partially restored and pancreatic ß-cell function did not improve.
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In a second recent randomised trial involving 60 obese patients with a history of at least 5 years of diabetes, Mingrone et al. reported no diabetes remission at 2 years in the medical-therapy group versus 75 % in the gastric-bypass group and 95 % in the biliopancreatic diversion group. Diabetes remission was defined as a fasting glucose < 100 mg/dl and HbA 1c < 6.5 % while taking no antidiabetic medications.
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All three studies are too small and the duration of follow-up is to short to draw conclusions on long-term efficacy of bariatric surgery on diabetes related morbidity and mortality compared with conventional medical therapy.
Recent results from the SOS, a large prospective non-randomised intervention trial, indicate that bariatric surgery also may be effective in diabetes prevention. There was an incidence rate of developing type gradual weight loss. Acute changes in the secretion of glucoregulatory gut hormones are not reported so far. 37 Different potential mechanisms by which RYGB directly improves glucose homeostasis have been suggested. The foregut hypothesis proposes that the exclusion of the proximal bowel prevents secretion of an unidentified signal that promotes insulin resistance and type 2 diabetes.
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By contrast, the hindgut hypothesis suggests that the rapid stimulation of the distal ileum by nutrients (as a result of the shortened length of the small bowel) improves glycaemia through the enhanced secretion of gut peptides such as glucagon-like peptide-1 (GLP-1), which augments glucose-dependent insulin secretion. 39, 40 Vertical sleeve gastrectomy, a procedure that does not result in shunting of the duodenum, does not favour the duodenal exclusion hypothesis.
This procedure results in an increase in gut hormones similar to that seen in RYGB. 41 Improved hepatic insulin sensitivity is noted immediately after RYGB due to energy restriction. Peripheral insulin sensitivity is improved later in response to the postoperative weight loss. 42, 43 Insulin secretion in response to an oral stimulus is significantly altered after RYGB, the postprandial rise in insulin concentration is earlier and reaches a higher peak level. 37, 44, 45 Insulin secretion after RYGB in response to an intravenous stimulus also changes, and a gradual increase in first phase insulin secretion is noted. 37, 46, 47 Other factors possibly contributing to improved glucose homeostasis have been described. A reduced secretion of ghrelin, a hormone that stimulates appetite and inhibits insulin is reported after RYGB. 48, 49 Other mechanisms implicated in glycaemic improvement could be changes in the rate of eating, gastric emptying, intestinal transit time, nutrient absorption and sensing. Alterations in the bile acid metabolism have also been described. There was also an improvement in hypertension and dyslipidaemia in, respectively, 58 % and 64 % of patients. The rate of minor surgical complications was 15 %, and there were no major complications or mortality. 53 A limitation of this study is that the definition of remission does not exactly follow that recommended by a consensus statement in 2009 (HbA 1c < 6 %).
17
Until now, no practical guidelines can be recommended for surgical approaches to diabetes in patients with a BMI < 35 kg/m². 54 The heterogeneity of studies is too large to draw good conclusions.
Long-term studies and large randomised controlled trials need to be performed. There needs to be a clear consensus on the definition of type 2 diabetes and the definition of remission. It also needs to be made clear whether the extent of sustained remission of type 2 diabetes is influenced by the extent of sustained weight loss, duration of diabetes, presurgery antidiabetic medications and the type of bariatric surgery.
Effects of Bariatric Surgery on Other Parameters
Bariatric surgery has also proven beneficial effects on other metabolic The SOS study has reported that after 10 years a statistically significant greater proportion of people who had received surgery had recovered from hypertension, hypertriglyceridaemia, low high-density lipoprotein cholesterol and hyperuricaemia. 55, 56 They reported also a reduced incidence of cancer and overall mortality in obese patients who underwent bariatric surgery as compared with conventional treatment. 14, 57 Furthermore, they noted a reduced number of cardiovascular deaths. The number of total first time cardiovascular events (myocardial infarction or stroke) was lower in the surgery group than in the control group. 58 Johnson et al. compared 2,580 adult obese patients with type 2 diabetes who underwent bariatric surgery with 2,580 controls in a retrospective 16 
Risks and Complications of Bariatric Surgery
The meta-analysis of Buchwald et al. reported a total mortality at < 30 days of 0.28 %, total mortality between 30 days and 2 years was 0.35 % 60 . Operative mortality is determined by several factors.
This can be patient-related, surgeon-related or facility-related. 61, 62 Preoperative variables that were found to be significant predictors of mortality in patients undergoing RYGB were a BMI > 50 kg/m², male sex, hypertension, known risk factors for pulmonary embolism and age > 45 years. 63 Early postoperative morbidity is clearly related to the complexity of the surgical procedure. Over 57,000 procedures were reviewed by the US Bariatric Longitudinal Database. The one or more complication at 1-year rates were 4.6 %, 10.8 %, 14.9 % and 25.7 % following LAGB, sleeve gastrectomy, RYGB and biliopancreatic diversion, respectively. 64 Bariatric surgery is most commonly complicated by anastomotic and staple-link leaks (3.1 %), wound infections (2.3 %), pulmonary events (2.2 %) and haemorrhage (1.7 %). 54 Late complications are mostly a consequence of disordered gastrointestinal tract function rather than failure of wound healing.
Nutritional deficiencies can result from poor oral intake due to anorexia, inadequate supplementation, prolonged vomiting or stricture formation or they can result from a failure of absorption. Deficiencies in fat-soluble vitamins A, D and K and deficiencies in vitamins B12, B1, C and folate are most commonly observed after RYGB and other malabsorptive procedures, 67, 68 which could lead to a variety of neurological complications. 69 Iron deficiency is reported in up to 50 % of premenopausal women who underwent a RYGB. 67 Calcium and vitamin D deficiency can lead to hyperparathyroidism and reduced bone density. 70, 71 Protein malnutrition and deficiencies in selenium, zinc and copper are also observed. 68 Another possible long-term complication of RYGB is reactive hypoglycaemia. In a review of the Swedish Bariatric Surgery registry, incidence rates of hospitalisation for post-gastric bypass hypoglycaemia were less than 1 %. 72 Reactive hypoglycaemia is usually mild and can be treated with a low-carbohydrate diet. In a small sample of 12 patients with hyperinsulinaemic hypoglycaemia after RYGB, Kellogs et al. reported substantial improvement of symptoms in six patients and moderate improvement in 10 patients after treatment with a low-carbohydrate diet. 73 In refractory cases, acarbose, octreotide, diazoxide and calcium channel blocker are empirically used, 74 but data on the effectiveness of these treatments in patients with hypoglycaemia following gastric bypass are scarce. Other possible complications are gastroesophageal reflux, 75, 76 bowel disturbances and cholelithiasis after rapid weight loss.
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Conclusion
Bariatric surgery has proven to be more effective in achieving sustained weight loss compared with lifestyle and medical interventions. In addition, there is a beneficial effect on co-morbidities as diabetes, hypertension, dyslipidaemia and sleep apnoea. Mortality and major morbidity rates are acceptable. In patients without diabetes, there is a clear consensus on the eligibility criteria for bariatric surgery. 15 However, much needs to be carried out to clarify the place of metabolic surgery in diabetes treatment algorithms. There needs to be a clear consensus on the definition of diabetes remission. Studies are necessary to establish preoperative predictors of diabetes remission, to make it possible to select the patients who will benefit from bariatric surgery. Whether bariatric surgery should be a rescue treatment for those patients who fail to achieve metabolic targets with standard therapy, or whether it should be offered to patients in an earlier stadium of the disease to prevent long-term diabetes morbidity and mortality should be examined. Larger, multicentre randomised trials with long-lasting follow-ups are needed to answer the question of whether patients with a BMI < 35 kg/m² are eligible for metabolic surgery.
It also needs to be clarified which type of procedure should be chosen, taking into account results on weight loss, rates of diabetes remission and duration of diabetes remission, improvement of other metabolic factors and effects on cardiovascular morbidity and mortality in the long term. 
